We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Experimental Cancer Drug Reverses Symptoms in Mouse Model of Alzheimer's Disease

By LabMedica International staff writers
Posted on 13 Apr 2015
Print article
Image: Star-like glial cells in red surround alpha-beta plaques in the cortex of a mouse with a model of Alzheimer\'s disease (Photo courtesy of Strittmatter laboratory/Yale University).
Image: Star-like glial cells in red surround alpha-beta plaques in the cortex of a mouse with a model of Alzheimer\'s disease (Photo courtesy of Strittmatter laboratory/Yale University).
An experimental, but clinically disappointing drug for treatment of cancer has been found to be extremely effective in reversing the symptoms of Alzheimer's disease (AD) in a mouse model.

The drug, AZD05030 (Saracatinib), developed by Astra Zeneca (London, United Kingdom) is a potent Src inhibitor to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR. As investigators at Yale University (New Haven, CT, USA) were aware that the Fyn tyrosine kinase was implicated in AD pathology where it was triggered by amyloid-beta oligomers (A-beta o) and propagated by Tau; the theorized that Fyn inhibition would prevent or delay disease progression.

To this end they sought to repurpose the Src family kinase inhibitor cancer drug, AZD0530, for AD. Initially they evaluated the pharmacokinetics and distribution of AZD0530 in mice. Inhibition of A-beta o signaling to Fyn, Pyk2, and Glu receptors by AZD0530 was tested by brain slice assays. After AZD0530 or vehicle treatment of wild-type and AD transgenic mice, memory was assessed by Morris water maze and novel object recognition. For these cohorts, amyloid precursor protein (APP) metabolism, synaptic markers (SV2 and PSD-95), and targets of Fyn (Pyk2 and Tau) were studied by immunohistochemistry and by immunoblotting.

Results published in the March 21, 2015, online edition of the journal Annals of Neurology revealed that AZD0530 potently inhibited Fyn and prevented both A-beta o-induced Fyn signaling and downstream phosphorylation of the AD risk gene product Pyk2 in brain slices. After four weeks of treatment, AZD0530 dosing of APP/PS1 transgenic mice fully rescued spatial memory deficits and synaptic depletion, without altering APP or A-beta metabolism. AZD0530 treatment also reduced microglial activation in APP/PS1 mice, and rescued Tau phosphorylation and deposition abnormalities in APP/PS1/Tau transgenic mice. There was no evidence of AZD0530 chronic toxicity.

"With this treatment, cells under bombardment by beta amyloid plaques show restored synaptic connections and reduced inflammation, and the animal's memory, which was lost during the course of the disease, comes back," said senior author Dr. Stephen M. Strittmatter, professor of neurology at Yale University.

Related Links:

Yale University


New
Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Unit-Dose Packaging solution
HLX
New
ELISA System
ABSOL HS DUO
New
Silver Member
Static Concentrator
BJP 10

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Molecular Diagnostics

view channel
Image: The bowel cancer breakthrough could result in better treatment outcomes (Photo courtesy of 123RF)

New RNA Molecules Can Help Predict Bowel Cancer Return Recurrence

Colorectal cancer accounts for 10% of all cancer-related deaths worldwide and was ranked as the second most common cause of cancer death in the United States in 2022. Currently, clinicians face diagnostic... Read more

Hematology

view channel
Image: QScout CBC will give a complete blood count in 2 minutes from fingerstick or venous blood (Photo courtesy of Ad Astra Diagnostics)

Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results

Every hour is critical in protecting patients from infections, yet there are currently limited tools to assist in early diagnosis before patients reach a hospital. The complete blood count (CBC) is a common... Read more

Microbiology

view channel
Image: The InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection (Photo courtesy of 123RF)

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

Periprosthetic joint infection (PJI) represents a significant global issue that is worsening as the number of joint replacements increases due to aging populations. In the United States alone, the anticipated... Read more

Pathology

view channel
Image

AI-Based Method Shows Promise for Pathological Diagnosis of Hereditary Kidney Diseases

Alport syndrome is a hereditary kidney disorder characterized by kidney dysfunction, sensorineural hearing loss, and ocular abnormalities. Early in the disease, patients experience hematuria, which is... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.